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Radiation therapy (XRT) is an important modality for treatment of breast cancer. Its use has
occasionally resulted in the development of secondary malignancies.
We describe this interesting case of a 46-year-old woman who developed malignant fibrous
histiocytoma in the contralateral breast 6 years after a lumpectomy followed by radiation therapy
for infiltrating ductal carcinoma. The role of XRT in the treatment of breast carcinoma and
development of Radiation induced Sarcoma (RIS) is examined.
RIS has a current incidence of 0.03% to 0.2% in patients undergoing XRT for breast carcinoma. The
role of XRT in the development of RIS has been clearly demonstrated. Clinical presentations vary,
and diagnosis is commonly delayed. Treatment consists of wide surgical excision. Development of
RIS has an average latency of over 10 years and correlates with the dose and technique of XRT.
Breast conserving surgery followed by irradiation is becoming increasingly popular leading to an
increasing number of sarcomas. Because of post-irradiation changes, detection of a new lesion is
difficult, resulting in delayed diagnosis and poor prognosis in these patients. However, the benefit
of XRT far outweighs the risk of RIS and should not affect the decision to treat these patients with
this modality.
Background
Radiation Induced Sarcomas were described following
treatment for tuberculous arthritis and in workers paint-
ing radium watch dials. Cahan et al [1] first described
(1948) the RIS diagnosis criteria which included a prior
history of radiation, latency period of 5 years/more, the
development of sarcoma within a previously irradiated
field, and a histological confirmation of sarcoma. These
criteria was later modified to include the tissues adjacent
to the radiated field and a shorter latency period of 3–4
years still continue to define RIS. The incidence of sarco-
mas in breast cancer patients following mastectomy and
chest wall irradiation is reported to be 0.2% at 10 years
[2].
RIS was first described in the setting of radical mastecto-
mies, and was later in patients undergoing lumpectomy
and radiation therapy. As breast conserving therapy
becomes more prevalent, it will be important to monitor
the frequency of this complication.
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We present a rare case of RIS in the contralateral breast out
of the field of radiation, after radiotherapy had been
administered 6 years earlier to the other side.
Case report
A 46 year old Caucasian woman was seen in the breast
clinic in Tralee General Hospital, Tralee, County Kerry,
Republic of Ireland (March, 95) with a 3 × 2 cms right
breast lump. Bilateral mammography followed by open
biopsy confirmed an adenocarcinoma in the upper outer
quadrant of the right breast. Left breast was normal. The
patient underwent simple mastectomy followed by radio-
therapy to right chest wall, axilla and supra-clavicular
fossa and chemotherapy with Cyclophosphamide, Meth-
otrexate and 5-FU. In February 2001 the same patient pre-
sented with a lump in the contralateral breast. The lump,
present for 6 months, was non-tender and slow growing.
Mammography figures as shown (Figures 1 and 2) Over-
lying skin tethering was present (Figure 3). No nipple dis-
charge or axillary lymphadenopathy was noted.
Cytology was graded as C1. Trucut specimen histology
showed cellular connective tissue with fibroblasts and
enlarged, hyperchromatic nuclei. Amid those desmopla-
sia were single histiocytes with granular foamy nuclei.
There was also cellular dense collagen involving adipose
tissue. Fibroblast proliferation accompanied by collagen
necrosis was extensive and was reported as post radiation
change.
The lump was excised. Specimen revealed a 3.2 cm central
tumor with a cyst 2 cm in dimension within. The tumor
arose in the soft tissue underlying the skin. A central cystic
cavity surrounded by extensive tumor necrosis was noted
along with a vascular tumor with fibrocellular nodules
surrounded by a network of collagen fibres. Some of the
nodules were hypercellular containing frequent mitoses.
There was an irregular infiltrating edge to the tumor into
the adipose tissue. The tumour was classified as a malig-
nant fibrous histiocytoma arising from the breast stroma/
subcutaneous tissue.
This was based on the finding of predominant storiform
pattern, and presence of epithelioid along with tumor
giant cells. The tumor had 2 parts, majority of low grade
differentiation. 1/3 rd was of high grade with >3 mitoses/
high power field. The patient was underwent left mastec-
tomy and axillary clearance. Histology confirmed tumour
clearance and no evidence of axillary node metastasis.
Body scan revealed no distant metastases.
Mammographic picture of breast lesion Figure 1
Mammographic picture of breast lesion.
Mammographic picture of breast lesion Figure 2
Mammographic picture of breast lesion.
Gross appearance of Breast lesion Figure 3
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Discussion
Post radiation changes following breast carcinoma treat-
ment include arm edema, brachial plexopathy, decreased
arm mobility, soft tissue necrosis, rib fractures, radiation
pneumonitis, radiation related heart disease and carcino-
genesis [3].
Primary malignant fibrous histiocytoma of the female
breast are rare. Clinically, radiation associated sarcomas
present as cutaneous lumps within the previously irradi-
ated area of the chest wall (parasternal area, supraclavicu-
lar fossa, shoulder girdle and conserved breast).
Mammography is typically negative [3-5] and the mean
latency period approximately 11 years (4 to 44 years).
Patients who developed RIS were young [6] when diag-
nosed with breast cancer (range 26 – 54 ; median 43
years) compared to patients with lymphangiosarcoma
(range 39 to 69 years, median 51 years) and the general
breast cancer population. The median age in a separate
study carried out at Institut Gustave Roussy (France) in
comparison were 65.8 years (49 – 83 years) and the mean
latent period was 9.5 years (4–24 years). The cumulative
incidence of sarcoma following irradiation of breast can-
cer was 0.2% (range 0.09 to 0.47) at 10 years. In a separate
retrospective analysis of RIS following XRT for breast can-
cer at Henri Mondor Hospital, France (1983 – 1997) [7]
RIS appeared with a latency period of 5 to 18 years (mean
10.3 years) and the mean age being 57.6 years (range 39
to 88 years).
Few studies have addressed the risk of contralateral breast
cancer after post operative RT. In a large cohort study of
41,109 patients diagnosed with breast cancer (1935 –
1982). RT was associated with a small but marginally sig-
nificant elevation in the risk of the contralateral breast
cancer [8] Patients aged 45 years or younger the risk of
contralateral breast cancer within 15 years was found to
be 11% without RT and increased to about 12–13% with
the addition of RT. The quantitative risk of Radiation
induced sarcoma following breast conserving radiother-
apy was no greater than that following mastectomy.
Patients receiving both XRT and chemotherapy was noted
to be at highest risk for secondary malignancies, including
sarcomas and leukaemias.
Radiation induced neoplastic transformation is thought
to be related to irreversible DNA damage [9]. Several years
following radiotherapy, dominant gene mutations and
gene deletions accumulate in the genome, making car-
cinogenesis a multistage process. Cells in G2 and M
phases of the cell cycle [10] are radiosensitive in terms of
both killing and induction of neoplastic transformation
compared with mid G1 phase. The exact molecular mech-
anisms of tumor promotion by ionizing radiation are
unknown. Proto-oncogene c-jun expression [11] and
inactivation of tumor suppressor genes p53 and Rb are
commonly discussed theories. The retinoblastoma locus
may be important in the pathogenesis of soft tissue sarco-
mas. Retinoblastoma gene alterations have been detected
in de novo leiomyosarcomas as well as RIS.
It is difficult to analyze the exact relationship between the
total irradiation dose and RIS. Minimum total doses of 10
Gy in conventional doses per fraction appear necessary to
result in RIS, most cases of RIS occur in association with
total radiation doses in the range of 40 – 50 Gy [12]. The
risk of carcinogenesis increases linearly with doses up to
10 Gy. Pierce et al [13] suggested a relationship between
radiation technique, potential overlapping of fields, and
the development of secondary tumors.
Current radiation therapy regimens consist of delivery of
5000 cGy to the whole breast at a dosage of 200 c Gy/day,
additional 1000–1500 cGy to the tumor bed. Postmastec-
tomy radiation is mainly reserved for patients with T3 or
T4 primary tumours or multiple positive lymph nodes.
Radiation associated sarcomas are usually high grade
tumors [6] reflected by the advanced stage at the time of
diagnosis. Pathological diagnosis is often delayed due to
lack of symptoms, distortion of histological architecture
and long latency period after diagnosis of the original
tumor.
Treatment
The treatment of choice for sarcomas of any histological
type, de-novo or post radiation exposure is a wide margin
resection, which can be challenging in chest wall sarcomas
because of proximity of vital structures. Centrally located
sarcomas often recur due to resection inadequacy.
Advanced soft tissue sarcomas need multimodality ther-
apy, surgical resection with chemotherapy and at times
radiotherapy are necessary. Okuno et al [14] has pub-
lished an extensive treatment review of advanced soft tis-
sue sarcomas with systemic therapy. Survival time varied
between 10–48 months [15] This poor survival was due to
delay in diagnosis, aggressive local nature of tumors and
truncal location, making radical extirpative surgery tech-
nically difficult. Experience with adjuvant chemotherapy
in RIS is limited and disappointing. Some investigators
believe that chemotherapy are of limited effectiveness in
RIS due to fibrotic tissue changes in the previously irradi-
ated field, thus preventing the chemotherapy from reach-
ing adequate concentrations in the target organ.
Conclusion
Although the role of radiation therapy in inducing the
development of sarcomas is evident, this risk is not
increasing with time, and the benefit offered by irradia-Publish with BioMed Central    and   every 
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tion in the treatment of breast cancer far outweighs the
risk of secondary malignancies and should not affect the
decision to treat a breast cancer patient with adjuvant XRT.
The long latency period, difficulty in detecting the tumor
clinically and histologically in previously irradiated tissue
(e.g., due to fibrosis) and inadequate biopsies makes the
detection and diagnosis of this condition a challenge.
Therefore, a high level of suspicion, careful patient evalu-
ation and adequate biopsy tissue for pathologic diagnosis
are mandatory.
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